查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1534957

干眼症市场：现况分析与预测（2024-2032）

Dry Eye Disease Market: Current Analysis and Forecast (2024-2032)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 132 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

由于干眼症患者病率不断上升、生物疗法的进步以及意识和诊断的提高，干眼症（DED）市场预计将以 4%左右的速度稳定成长。此外，新产品的推出是干眼症治疗市场成长的重要驱动力。一系列先进生物製剂、生物相似药、创新口服疗法和新疗法的推出，大幅增加了治疗干眼症的选择。这些市场发展不仅改善了患者的治疗效果，还有助于显着的市场扩张，为製药公司和医疗保健提供者提供了充满希望的机会。

依产品划分，市场分为人工泪液、抗发炎药、穿刺塞、促泌剂和其他产品。到2023年，人工泪液领域将占据重要的市场占有率，预计这一趋势将在预测期内持续下去。人工泪液通常被用作预防 DED 的第一道防线，因为它们可以立即缓解干燥、刺激和不适等症状。医疗保健专业人员广泛推荐针对不同程度干眼症状的患者使用人工泪液。它可以在柜檯轻鬆购买且价格合理，已成为许多寻求快速缓解 DED 症状的人的热门选择。

市场依通路分为医院药房、零售药房和线上药房。干眼症市场由医院药局市场主导。老年人口的增加、高住院率和干眼症的严重程度预计将推动这一领域的扩张。相反，零售药房行业占据干眼症治疗市场的第二大占有率。

为了更了解干眼症的市场介绍，市场分为北美（美国、加拿大等北美地区）、欧洲（德国、英国、法国、西班牙、义大利等欧洲地区）、亚太（中国、日本、印度等亚太地区）以及世界其他地区。在目前2023年的情况下，北美占据市场主导地位。这一优势可归因于推动该地区干眼症药物需求和开发的多个因素，包括高可支配收入、先进的医疗基础设施和不断提高的意识。市场上营运的主要公司包括AbbVie Inc.、Alcon Inc.、Akorn、Johnson &Johnson、Bausch Health Companies Inc.、Horus Pharma、Mitotech、Novaliq GmbH、OASIS Medical、 Otsuka Pharmaceutical Co. Ltd.。

目录

第1章 市场介绍

  • 市场定义
  • 主要目的
  • 利害关係人
  • 限制

第2章 研究方法或前提

  • 调查过程
  • 调查方法
  • 受访者简介

第3章 执行摘要

  • 行业概况
  • 依细分市场进行预测
    • 市场成长的力量
  • 区域展望

第4章 市场动态

  • 促进因素
  • 机会
  • 抑制因素
  • 趋势
  • PESTEL 分析
  • 需求方分析
  • 供给面分析
    • 併购
    • 投资场景
    • 产业洞察：主要新创公司及其独特策略

第5章 价格分析

  • 区域价格分析
  • 影响价格的因素

第6章 2022-2032年全球干眼症市场营收

第7章 依产品细分市场

  • 人工泪液
  • 抗发炎药
  • 泪点塞
  • 分泌增强剂
  • 其他产品

第8章 依通路细分的市场

  • 医院药房
  • 零售药局
  • 网路药局

第9章 依地区划分的市场分析

  • 北美
    • 美国
    • 加拿大
    • 其他北美地区
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区

第10章 价值链分析

  • 进入市场的公司名单

第11章 竞争态势

  • 竞争对手仪表板
  • 竞争市场定位分析
  • 波特五力分析

第12章 公司简介

  • 艾伯维公司
    • 公司概况
    • 主要财务状况
    • SWOT分析
    • 产品组合
    • 近期趋势
  • Alcon Inc.
  • Akorn
  • Johnson & Johnson
  • Bausch Health Companies Inc.
  • Horus Pharma
  • Mitotech
  • Novaliq GmbH
  • OASIS Medical
  • Otsuka Pharmaceutical Co. Ltd

第13章 缩写与假设

第14章 附录

简介目录
Product Code: UMHE212956

Dry Eye Disease (DED) is a common, frequently chronic, and frequently poorly controlled disease affecting millions of people. Since there is inadequate tear film on the outer surface of the eye, DED causes discomfort, and visual changes and may harm the surface of the eye if not treated. It is a complex disease that develops gradually in relation to the external environment and a person's lifestyle, and it depends on age, hormonal background, and other factors. Some of the market drivers include rising incidence of dry eye disease, development of new methods of management, and general awareness on the disease. For instance, as per the data of America Academy of Ophthalmology, approximately 20 million people in the United States are currently living with dry eye disease (DED), and that number is growing in both young and old adults. Further, about 250 million people are living with dry eye disease.

The Dry Eye Disease Market is expected to grow at a steady rate of around 4% due to rising prevalence of dry eye disease, advancements in biologic therapies, and increased awareness and diagnosis. Further, new product launches are a critical driver of growth in the dry eye disease treatment market. The introduction of advanced biologic therapies, biosimilars, innovative oral therapies, and a robust pipeline of emerging treatments are significantly enhancing the options available for managing dry eye disease. These developments not only improve patient outcomes but also contribute to the substantial expansion of the market, offering promising opportunities for pharmaceutical companies and healthcare providers.

Based on the Product, the market is segmented into Artificial Tears, Anti-inflammatory Drugs, Punctal Plugs, Secretagogues, and Other Products. In 2023, the artificial tears segment held a significant share of the market, which is expected to persist during the forecast period. Artificial tears are commonly used as the first line of defense against DED due to their effectiveness in providing immediate relief from symptoms such as dryness, irritation, and discomfort. Artificial tears are widely recommended by healthcare professionals for patients with varying degrees of dry eye symptoms. Their easy accessibility over-the-counter and affordability make them a popular choice for many individuals seeking quick relief from DED.

Based on the distribution channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. The dry eye disease market is dominated by the hospital pharmacy segment. The senior population's rise, high hospitalization rates, and the severity of dry eye disease are predicted to fuel the segment's expansion. Conversely, the market for treatments for Dry Eye Disease was dominated by the retail pharmacy sector, which had the second-largest share.

For a better understanding of the market adoption of Dry Eye Disease, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2023. This dominance can be attributed to several factors that drive the demand and development of dry eye disease therapeutics in the region, such as high disposable income, advanced healthcare infrastructure, and rising awareness. Some of the major players operating in the market include AbbVie Inc, Alcon Inc., Akorn, Johnson & Johnson, Bausch Health Companies Inc., Horus Pharma, Mitotech, Novaliq GmbH, OASIS Medical, and Otsuka Pharmaceutical Co. Ltd.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Dry Eye Disease Market
  • 2.2. Research Methodology of the Dry Eye Disease Market
  • 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

  • 3.1. Industry Synopsis
  • 3.2. Segmental Outlook
    • 3.2.1. Market Growth Intensity
  • 3.3. Regional Outlook

4.MARKET DYNAMICS

  • 4.1. Drivers
  • 4.2. Opportunity
  • 4.3. Restraints
  • 4.4. Trends
  • 4.5. PESTEL Analysis
  • 4.6. Demand Side Analysis
  • 4.7. Supply Side Analysis
    • 4.7.1. Merger & Acquisition
    • 4.7.2. Investment Scenario
    • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

  • 5.1. Regional Pricing Analysis
  • 5.2. Price Influencing Factors

6.GLOBAL DRY EYE DISEASE MARKET REVENUE (USD BN), 2022-2032F

7.MARKET SEGMENT BY PRODUCT

  • 7.1. Artificial Tears
  • 7.2. Anti-inflammatory Drugs
  • 7.3. Punctal Plugs
  • 7.4. Secretagogues
  • 7.5. Other Products

8.MARKET SEGMENT BY DISTRIBUTION CHANNEL

  • 8.1. Hospital Pharmacy
  • 8.2. Retail Pharmacy
  • 8.3. Online Pharmacy

9.MARKET INSIGHTS BY REGION

  • 9.1. North America
    • 9.1.1. U.S.
    • 9.1.2. Canada
    • 9.1.3. Rest of North America
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. U.K.
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Rest of Asia-Pacific
  • 9.4. Rest of World

10.VALUE CHAIN ANALYSIS

  • 10.1. List of Market Participants

11.COMPETITIVE LANDSCAPE

  • 11.1. Competition Dashboard
  • 11.2. Competitor Market Positioning Analysis
  • 11.3. Porter Five Forces Analysis

12.COMPANY PROFILED

  • 12.1. AbbVie Inc
    • 12.1.1. Company Overview
    • 12.1.2. Key Financials
    • 12.1.3. SWOT Analysis
    • 12.1.4. Product Portfolio
    • 12.1.5. Recent Developments
  • 12.2. Alcon Inc.
  • 12.3. Akorn
  • 12.4. Johnson & Johnson
  • 12.5. Bausch Health Companies Inc.
  • 12.6. Horus Pharma
  • 12.7. Mitotech
  • 12.8. Novaliq GmbH
  • 12.9. OASIS Medical
  • 12.10. Otsuka Pharmaceutical Co. Ltd

13.ACRONYMS & ASSUMPTION

14.ANNEXURE